The MET oncogene is a growth factor receptor that is altered in many forms of cancer including lung and colon carcinomas as well as several forms of melanoma. One assay for characterizing the gene composition of tumor cells is Fluorescence in situ Hybridization (FISH) in which a fluorescently labeled DNA is used to show the presence of and level (i.e. number copies) of a gene inside cells. The experiment below is a FISH assay of two different tumor samples (Patient D and Patient E) using a MET gene probe labeled with a green fluorescent probe. The figure on the right presents the survival data from diagnosis of cancer patients with FISH data similar to Patient D or E. Based on this data, what has happened to the MET gene in Patient D population that has made their cancer more severe and reduced survival time (Limit 4-5 sentences). D Survival rate (%) 2 100 0 0 100 200 Time (days) 300 E

The MET oncogene is a growth factor receptor that is altered in many forms of cancer including lung and colon carcinomas as well as several forms of melanoma. One assay for characterizing the gene composition of tumor cells is Fluorescence in situ Hybridization (FISH) in which a fluorescently labeled DNA is used to show the presence of and level (i.e. number copies) of a gene inside cells. The experiment below is a FISH assay of two different tumor samples (Patient D and Patient E) using a MET gene probe labeled with a green fluorescent probe. The figure on the right presents the survival data from diagnosis of cancer patients with FISH data similar to Patient D or E. Based on this data, what has happened to the MET gene in Patient D population that has made their cancer more severe and reduced survival time (Limit 4-5 sentences). D Survival rate (%) 2 100 0 0 100 200 Time (days) 300 E

Human Heredity: Principles and Issues (MindTap Course List)

11th Edition

ISBN:9781305251052

Author:Michael Cummings

Publisher:Michael Cummings

Chapter14: Biotechnology And Society

Section: Chapter Questions

Problem 13QP

See similar textbooks

Similar questions

Telomerase is an attractive cancer target since 85% - 90% of tumors express telomerase (while normal cells express little to no telomerase). One paradigm in this model is the “cancer stem cell” hypothesis. Cancer stem cells (or tumor-initiating cells with stem-cell like properties) can self-renew, as well as give rise to heterogeneous tumor cell populations (essentially, they are believed to be responsible for the formation and maintenance of the tumor). If these cells are indeed “stem-like” they also divide more slowly, and presumably express telomerase (like normal stem cells).Do you think a treatment strategy that inhibits telomerase would be effective in treating cancer? How does the cancer stem cell hypothesis complicate or compliment these strategies? Justify your answer.
Why is it important to model cancer through the generation of induced pluripotent stem cells ? Explain in detail the main findings. Please sort as a list.
Describe briefly how MALDI and two-dimensional poly acrylamide gel electrophoresis could be used to identify a protein expressed in cancer cells but not in normal healthy cells.
On the image, you can see the results of a DNA microarray used for cancer prognosis, where tissue samples from healthy and cancerous tissues were analyzed. cDNA from healthy cells and cancer cells were labeled with green and red fluorescence, respectively, mixed equally, and hybridized with the chip. It is known that gene A is more highly expressed in breast cancer type I, while genes B and C have lower expression in type II, which is highly aggressive. Based on the gene expression levels shown in the image, the cancer sample does not correspond to either type I or type II breast cancer, why is that?
Tumor-suppressor genes are normal human genes that prevent uncontrollable cell growth. Starting with a normal laboratory humancell line, describe how you could use transposon tagging to identifytumor-suppressor genes. (Note: When a TE hops into a tumorsuppressorgene, it may cause uncontrolled cell growth. This is detected as a large clump of cells among a normal monolayer of cells.)
You plan to synthesize a peptide to be used as a vaccine to treat melanoma, a particularly aggressive form of skin cancer. Normally, gp100, a protein on the surface of melanocytes, activates cell growth when it is bound by its ligand. Activation of the growth pathway depends on the presence of threonine in the ligand. The effective peptide vaccine will mimic the natural ligand, but won’t cause cell growth and division. Below is the sequence of the natural ligand: LDMKTAG In order to ensure your newly designed peptide vaccine does not cause cell growth upon binding, you must substitute the Threonine residue at position 5. What amino acid would you replace it with, bearing in mind that the peptide should still be similar enough to bind to the gp100 protein in the surface of melanocytes. Explain your choice. Your vaccine will be administered as a topical cream, and you require your peptide to have an overall neutral charge in order to be functional. At what pH should you formulate…
Why is it important to model cancer through the generation of induced pluripotent stem cells ? Explain in detail the main findings.
BugRx is a new biotechnology company in Cambridge, Massachusetts, developing human monoclonal antibodies made in insect cells. The CEO, Dr. Bugsbunny, has convened a Board Meeting to discuss research proposals and budgets. The VP of Research & Development, Karen Hucklebug, gives an update on the Factor 801A program. Factor 801A is new signal transduction molecule that is important for the growth of ovarian cancer cells. She explains that the structure of the antibody binding to 810A has been finalized and production is on schedule in Luv Bug, Ireland. The CMO, Dr. David Sprayberry, reminds the Board that several pathologists have reported high levels of Factor 801A in ovarian cancer cells and it is a significant prognostic factor. The American Cancer Society estimates that 14,070 women died of ovarian cancer in the United States in 2018. The VP of Marketing, Andrew Flynn, asks about the current treatments for ovarian cancer. David explains that most ovarian cancers spread through…
BugRx is a new biotechnology company in Cambridge, Massachusetts, developing human monoclonal antibodies made in insect cells. The CEO, Dr. Bugsbunny, has convened a Board Meeting to discuss research proposals and budgets. The VP of Research & Development, Karen Hucklebug, gives an update on the Factor 801A program. Factor 801A is new signal transduction molecule that is important for the growth of ovarian cancer cells. She explains that the structure of the antibody binding to 810A has been finalized and production is on schedule in Luv Bug, Ireland. The CMO, Dr. David Sprayberry, reminds the Board that several pathologists have reported high levels of Factor 801A in ovarian cancer cells and it is a significant prognostic factor. The American Cancer Society estimates that 14,070 women died of ovarian cancer in the United States in 2018. Give an example of a technique that can be used to measure the affinity of the antibody for Factor 801A? Explain how it works David adds that an…
BugRx is a new biotechnology company in Cambridge, Massachusetts, developing human monoclonal antibodies made in insect cells. The CEO, Dr. Bugsbunny, has convened a Board Meeting to discuss research proposals and budgets. The VP of Research & Development, Karen Hucklebug, gives an update on the Factor 801A program. Factor 801A is new signal transduction molecule that is important for the growth of ovarian cancer cells. She explains that the structure of the antibody binding to 810A has been finalized and production is on schedule in Luv Bug, Ireland. The CMO, Dr. David Sprayberry, reminds the Board that several pathologists have reported high levels of Factor 801A in ovarian cancer cells and it is a significant prognostic factor. The American Cancer Society estimates that 14,070 women died of ovarian cancer in the United States in 2018 Propose a PK protocol (~100 words) to study the distribution of the antibody to Factor 801A after IP injection in mice. …
BugRx is a new biotechnology company in Cambridge, Massachusetts, developing human monoclonal antibodies made in insect cells. The CEO, Dr. Bugsbunny, has convened a Board Meeting to discuss research proposals and budgets. The VP of Research & Development, Karen Hucklebug, gives an update on the Factor 801A program. Factor 801A is new signal transduction molecule that is important for the growth of ovarian cancer cells. She explains that the structure of the antibody binding to 810A has been finalized and production is on schedule in Luv Bug, Ireland. The CMO, Dr. David Sprayberry, reminds the Board that several pathologists have reported high levels of Factor 801A in ovarian cancer cells and it is a significant prognostic factor. The American Cancer Society estimates that 14,070 women died of ovarian cancer in the United States in 2018 Propose a protocol (~100 words) to study the efficacy of the antibody in this mouse model.
BugRx is a new biotechnology company in Cambridge, Massachusetts, developing human monoclonal antibodies made in insect cells. The CEO, Dr. Bugsbunny, has convened a Board Meeting to discuss research proposals and budgets. The VP of Research & Development, Karen Hucklebug, gives an update on the Factor 801A program. Factor 801A is new signal transduction molecule that is important for the growth of ovarian cancer cells. She explains that the structure of the antibody binding to 810A has been finalized and production is on schedule in Luv Bug, Ireland. The CMO, Dr. David Sprayberry, reminds the Board that several pathologists have reported high levels of Factor 801A in ovarian cancer cells and it is a significant prognostic factor. The American Cancer Society estimates that 14,070 women died of ovarian cancer in the United States in 2018. The VP of Marketing, Andrew Flynn, asks about the current treatments for ovarian cancer. David explains that most ovarian cancers spread through…